Development of a peptide-siRNA nanocomplex targeting NF- κB for efficient cartilage delivery by Yan, Huimin et al.




Development of a peptide-siRNA nanocomplex
targeting NF- κB for efficient cartilage delivery
Huimin Yan
Washington University School of Medicine in St. Louis
Xin Duan
Washington University School of Medicine in St. Louis
Hua Pan
University of South Florida
Antonina Akk
Washington University School of Medicine in St. Louis
Linda J. Sandell
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Yan, Huimin; Duan, Xin; Pan, Hua; Akk, Antonina; Sandell, Linda J.; Wickline, Samuel A.; Rai, Muhammad Farooq; and Pham,




Huimin Yan, Xin Duan, Hua Pan, Antonina Akk, Linda J. Sandell, Samuel A. Wickline, Muhammad Farooq
Rai, and Christine T. N. Pham
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/7641
1SCIeNTIFIC RePoRTS |           (2019) 9:442  | DOI:10.1038/s41598-018-37018-3
www.nature.com/scientificreports
Development of a peptide-siRNA 
nanocomplex targeting NF- κB for 
efficient cartilage delivery
Huimin Yan1, Xin Duan2, Hua Pan3, Antonina Akk1, Linda J. Sandell2, Samuel A. Wickline3, 
Muhammad Farooq Rai  2,4 & Christine T. N. Pham  1,5
Delivery of therapeutic small interfering RNAs (siRNAs) in an effective dose to articular cartilage is very 
challenging as the cartilage dense extracellular matrix renders the chondrocytes inaccessible, even 
to intra-articular injections. Herein, we used a self-assembling peptidic nanoparticle (NP) platform 
featuring a cell penetrating peptide complexed to NF-κB p65 siRNA. We show that it efficiently and 
deeply penetrated human cartilage to deliver its siRNA cargo up to a depth of at least 700 μm. To 
simulate osteoarthritis in vitro, human articular cartilage explants were placed in culture and treated 
with IL-1β, a cytokine with known cartilage catabolic and pro-inflammatory effects. Exposure of 
peptide-siRNA NP to cartilage explants markedly suppressed p65 activation, an effect that persisted 
up to 3 weeks after an initial 48 h exposure to NP and in the presence of continuous IL-1β stimulation. 
Suppression of IL-1β-induced p65 activity attenuated chondrocyte apoptosis and maintained cartilage 
homeostasis. These findings confirm our previous in vivo studies in a murine model of post-traumatic 
osteoarthritis and suggest that the ability of peptide-siRNA NP to specifically modulate NF-κB 
pathway, a central regulator of the inflammatory responses in chondrocytes, may potentially mitigate 
the progression of cartilage degeneration.
Osteoarthritis (OA) represents the most common form of arthritis and is a major cause of morbidity in the 
aging population. The annual health care burden for OA is $185 billion based on 2007 data, reflecting its very 
high prevalence in society and its negative quality of life impact1. Despite its prevalence, there are few treatment 
options—beside intermittent intra-articular (IA) corticosteroid or hyaluronic acid injections that are of question-
able benefits2,3 — and no disease-modifying OA drugs (DMOADs).
IA delivery of therapeutics is ideal for the treatment of OA, a disease that usually affects a few large joints. It 
offers direct access to the joint space, thus increasing local concentration of the drugs while limiting systemic 
side effects. Despite clear advantages and critical medical need, successful DMOAD development for IA delivery 
remains a challenge and none has successfully emerged in clinic. The reasons for this failure are multifold. Most 
drugs delivered IA are rapidly cleared from the joint cavity and have difficulty reaching chondrocytes residing in 
the avascular cartilage due to the dense extracellular matrix. In addition, primary OA is not a single disease but a 
syndrome with multiple etiologies that are still poorly understood.
Post-traumatic OA (PTOA) is a form of OA that develops after a joint injury and in which the nature and 
time of trauma is generally known. Approximately 12% of the overall OA burden can be traced to joint trauma4 
but true prevalence for PTOA may be higher, given the long delay (10–15 years) between injury and end-stage 
PTOA5. Studies have documented a robust inflammatory response in the immediate aftermath of joint injury 
(i.e. during the first week and up to 2–3 months) that persists for months to years, albeit at a lower level6. This 
inflammatory response likely contributes to chondrocyte death, impaired cartilage repair and subsequent carti-
lage degeneration that constitute PTOA6.
We have developed a peptidic nanoparticle (NP) that suppresses NF-κB activities via small interfering RNAs 
(siRNAs). Using a murine model of non-invasive controlled injurious compressions of the knee joint that allowed 
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the examination of cartilage responses at specific time points after trauma, we showed that joint injury led to 
NF-κB activation within hours. IA delivery, immediately after injury, of a NP comprising a peptide, p5RHH 
complexed to p65 siRNA suppressed NF-κB expression and significantly reduced two important early events: 
chondrocyte apoptosis and reactive synovitis7.
In anticipation of translating this technology to the point of care, we tested the efficacy of p5RHH-NF-κB p65 
siRNA NP in human articular cartilage explants as a proof-of-concept that our platform can eventually translate 
to the clinic. To this end, we showed that the peptide-siRNA NP freely and deeply penetrated all layers of the 
much thicker human cartilage explants to deliver its siRNA cargo to the chondrocytes. In addition, the siRNA 
signal was detected in chondrocytes for up to 21 days7 and p65 suppression persisted for up to 3 weeks. These 
promising findings warrant further investigation into the long-term outcomes studies in rodent models of PTOA 
and further validation in a large animal model.
Results
NF-κB siRNA NP efficiently transfects human umbilical endothelial cells (HUVECs) and chon-
drocytes in vitro. The self-assembling p5RHH-siRNA NP was formulated as previously described8. Briefly, 
p5RHH (20 mM stock solution) was dissolved 1:400 in Opti-mem followed by the addition of a smart pool of 
4 human p65 siRNAs (50 nM final concentration). The preparation was incubated at 37 °C for 40 min yielding 
peptide-siRNA NP that measured ∼55 ± 18 nm by wet mode atomic force microscopy8,9 and had a zeta potential 
of ~12 ± 0.7 mV9. In addition, we have already shown that this 40 min incubation exhibits maximal transfection 
efficiency in vitro8.
We first tested the ability of p5RHH-p65 siRNA NP to knockdown p65 expression in HUVECs. Delivery of 
human p65 siRNA NP led to marked decrease in p65 expression in these cells and exhibited similar or superior 
transfection efficiency compared with Lipofectamine (Fig. 1A). NP containing the scrambled siRNA sequences 
on the other hand did not silence p65 expression in HUVECs (Fig. 1A). Next, we examined the uptake of 
p5RHH-Cy3-labeled siRNA NP in human primary chondrocytes. We observed that p5RHH-siRNA NP, but not 
free Cy3-labeled siRNA, was taken up by the chondrocytes (Fig. 1B). These results confirmed the specificity of the 
p65 siRNAs as well as the transfection efficiency of the NP.
NF-κB siRNA NP suppresses p65 in IL-1β-treated human cartilage explants. To enhance the 
expression of NF-κB, we exposed human articular cartilage explants to IL-1β, a cytokine with known catabolic 
Figure 1. p5RHH-p65 siRNA NP transfects HUVECs, human chondrocytes, and cartilage explants to suppress 
p65. (A) HUVECs were cultured to 50% confluence and transfected with p65 siRNA (RELA SMART pool, 
100 μM F.C.) or scrambled siRNA delivered byLipofectamine or peptide-siRNA nanocomplex. p65 expression 
was detected by Western blot. Actin served as protein loading control. (B) Human primary chondrocytes were 
cultured as detailed in Materials and Methods and transfected with p5RHH-Cy3–labeled siRNA NP or free 
Cy3-labeled siRNA for 48 h. Cy3-siRNA (red) in chondrocytes was visualized by confocal microscopy. IL-1β 
stimulated human cartilage explants were incubated with p5RHH-p65 siRNA (p65 NP with 500 nM siRNA) 
or scrambled siRNA (scram NP) for 48 h after which the excess NP was washed off and cartilage stained and 
analyzed or cultured in the presence of IL-1β (10 ng/ml) for a total of 4 weeks. (C) Immunofluorescence of p65 
(green) in cartilage sections at day 7 following different treatments. Bottom row: representative 2D confocal 
images at higher magnification. (D) Mean fluorescence of P-p65 per chondrocyte (from z-stack confocal 
images) 48 h after IL-1 β and NP exposure. (E) Relative mean fluorescence of P-p65 per chondrocyte at different 
time points. Mean P-p65 fluorescence in cartilage exposed to scrambled siRNA NP was set at 1. Mean reflects 
analysis of 5–8 areas per explant, each including 3–6 cells; 3–5 individual cartilage explants were analyzed per 
treatment per time point. **P < 0.01, ***P < 0.001; n.s. not significant. COL2 (red), type II collagen; DAPI 
(blue) stained nuclei.
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and a pro-inflammatory effects on cartilage10. We confirmed that IL-β exposure led to significant activation of 
p65, as evidenced by an increase in its phosphorylation and nuclear translocation (Fig. 1C,D). Treatment with 
NF-κB NP markedly suppressed IL-1β-mediated p65 activation, an effect that was apparent 48 h after NP expo-
sure (Fig. 1C) and lasted up to 3 weeks after the initial exposure (Fig. 1E).
NF-κB siRNA NP preserves chondrocyte viability and maintains cartilage homeostasis. We 
have previously demonstrated that mechanical joint injury in vivo activates NF-κB signaling, leading to chon-
drocyte apoptosis7, a pathological feature of PTOA. NF-κB activation promotes the release of pro-inflammatory 
cytokines such as IL-1β, which has been shown to induce apoptosis in human articular chondrocytes11, thus 
providing a useful in vitro model of OA. Here we show that exposure of human cartilage explants to IL-1β indeed 
led to chondrocyte apoptosis, as evidenced by nuclear localization of poly(ADP-ribose) polymerase (PARP) 
C-terminal cleavage fragment (Fig. 2A,B). To determine whether NF-κB siRNA NP suppressed IL-1β-induced 
apoptosis of chondrocytes, we exposed human cartilage explants to p5RHH-p65 siRNA NP (500 nM) for 48 h 
while maintaining the explants under continuous IL-1β stimulation. Consistent with in vivo studies7, exposure 
Figure 2. p5RHH-p65 siRNA NP attenuates chondrocyte apoptosis and maintains cartilage homeostasis. IL-
1β-treated human cartilage explants were incubated with p5RHH-p65 siRNA NP (p65 NP) or scrambled siRNA 
NP (scram NP) as detailed above. (A) Immunofluorescence of cleaved PARP (cPARP) (green) in cartilage 
sections at day 7. (B) Number of cells with nuclear cPARP at 48 h and (C) at 14 days after IL-1 β exposure and 
NP treatment. (D) Immunofluorescence of LC3 in cartilage sections without and with IL-1β exposure at day 7. 
(E) Mean fluorescence of LC3 per chondrocyte after exposure to IL-1β at day 7 and (F) at different time points 
after exposure to NP treatment. Mean reflects analysis of 5–8 areas, each including 3–6 cells, n = 3–5 individual 
cartilage explants were analyzed per treatment per time point. *P < 0.05, **P < 0.01, ***P < 0.001; n.s. not 
significant. COL2 (red), type II collagen; DAPI (blue) stained nuclei.
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of cartilage explants to NP did not affect cell viability at the articular surface (Fig. S1). In addition, p5RHH-p65 
siRNA NP significantly inhibited nuclear localization of cleaved PARP (an indication of apoptosis), an effect that 
was evident one week after the NP exposure and lasted at least until week 2 (Fig. 2C).
Normal chondrocytes express high level of the autophagy-related gene (Atg) called microtubule-associated 
protein light chain 3 (LC3) and its expression decreases with aging and OA12. Our data revealed that exposure 
of human cartilage explants to IL-1β significantly reduced the expression of LC3 (Fig. 2D,E). Treatment of the 
explants with p5RHH-p65 siRNA NP, but not the p5RHH -scrambled siRNA NP, preserved LC3 expression 
(Fig. 2F). Moreover, p5RHH-p65 siRNA NP blocked the nuclear translocation of β-catenin (Fig. 3A–C), the 
effector of canonical Wnt signaling, a pathway implicated in OA13. Consistent with these results we found that 
the expression of Wnt3a, the prototypical activator of the β-catenin-dependent canonical pathway14 was similarly 
suppressed (Fig. 3D–F).
NF-κB modulates the expression of complement in cartilage. The complement system plays a cen-
tral role in innate immunity and participates in many disease processes. Accumulating evidence suggests that 
complement activation contributes to OA pathogenesis15. Expression of many complement proteins, including 
C3, C4, and factor B is reported in OA cartilage, synovial membrane, and cultured chondrocytes15. Moreover 
their expression is amplified by IL-1β stimulation15. In contrast mice lacking in certain complement proteins, such 
as C5, are protected against OA development16. Consistent with published results we observed a marked upreg-
ulation of C3 in human cartilage explants with IL-1β stimulation (Fig. 3G,H). Treatment of cartilage explants 
with p5RHH-p65 siRNA NP significantly suppressed C3 expression (Fig. 3I). This finding uncovers a crosstalk 
between NF-κB signaling and complement regulation in a joint-associated tissue.
Discussion
In previous studies, we have shown that the p5RHH-siRNA nanocomplex efficiently penetrated the dense extra-
cellular matrix to deliver its siRNA cargo to all the layers of human articular cartilage7. We have also shown 
that fluorescently labeled siRNA persisted within chondrocyte lacunae for up to 3 weeks after the initial expo-
sure to NP7. In this study, we show that an initial exposure of p5RHH-siRNA NP led to significant suppres-
sion of p65 expression in IL-1β-treated human cartilage explants, an effect that persisted for at least 3 weeks. 
Suppression of p65 expression was accompanied by maintenance of chondrocyte viability (evidenced by decrease 
in nuclear localization of cleaved PARP) and cartilage homeostasis (evidenced by preservation of LC3 expres-
sion). Serendipitously we also found that p5RHH-siRNA NP modulated the crosstalk between NF-κB signaling 
Figure 3. p5RHH-p65 siRNA NP modulates crosstalk between NF-κB and Wnt signaling/complement 
system. IL-1β stimulated human OA cartilage explants were incubated with p5RHH-p65 siRNA NP (p65 
NP) or scrambled siRNA NP (scram NP) in the presence of IL-1β as detailed above for a total of 2 weeks. 
Immunofluorescence of β-catenin (A), Wnt3a (D), and C3 (G) in cartilage sections at day 7 without and with 
IL-1β treatment. Mean fluorescent intensity of β-catenin (B), Wnt3a (E), and C3 (H) per chondrocyte (from 
z-stack confocal images) 48 h following IL-1 β exposure. Mean fluorescent intensity (MFI) of β-catenin (C), 
Wnt3a (F), and C3 (I) per chondrocyte at different time points after exposure to NP treatment. Mean reflects 
analysis of 5–8 areas per explant, each including 3–6 cells; 3–5 individual cartilage explants were analyzed per 
treatment per time point. *P < 0.05, **P < 0.01, ***P < 0.001; n.s. not significant. COL2 (red), type II collagen; 
DAPI (blue) stained nuclei.
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pathway and the complement system. Thus exploring the role of complement in the joint may, in the future, offer 
novel therapeutic strategies for OA treatment.
Much interest has recently focused on the role of inflammation and inflammatory cytokines in the pathogen-
esis of PTOA (and possibly primary OA). It is posited that an imbalance between inflammatory/catabolic and 
anabolic cytokines lead to cartilage degeneration, a hallmark of PTOA. Thus, blockade of catabolic cytokines such 
as TNF-α and IL-1β has gained attention as potential therapy. Indeed, IA administration of IL-1 receptor antag-
onist (IL1-ra) exhibits disease-modifying effects in a rodent model of PTOA17. In clinical studies, however, the 
administration of commercially available IL-1ra (Anakinra) did not show any therapeutic effects in established 
knee OA in humans18. These studies suggest that targeting IL-1β pathway is unlikely to impact the progression of 
OA once established. However, anti-NF-κB nanotherapy administered in the acute phase, post-joint injury may 
improve long-term primary outcomes of PTOA.
The NF-κB pathway is the central regulator of the inflammatory responses in synovium and chondrocytes19, 
leading to the expression of inflammation-related genes, including TNF-α, IL-1β, IL-6, nitric oxide (NO), 
matrix-degrading metalloproteases (MMPs), and the ADAMTS family of aggrecanases. NF-κB pathway thus 
represents an attractive therapeutic target for PTOA. However, the indiscriminate systemic blockade of NF-κB 
poses significant risks, given its central role in host immune responses. As targeted strategies to silence NF-κB 
only in affected joints via IA delivery might help avoid unwanted systemic effects, they are highly desirable. We 
have shown in vitro (in human cartilage explants) and in vivo (in rodent model of PTOA) that our p5RHH-siRNA 
nanoplatform targeting NF-κB can overcome the difficulties in therapeutic delivery to articular cartilage and 
promises real translational potential as a disease-modifying IA therapy in the treatment of PTOA. Long-term 
outcomes studies in rodent models of PTOA and further validation in a large animal model are currently under-
way in our laboratory. We acknowledge that targeting NF-κB alone may fail to modify the long-term outcomes 
of PTOA. If this were the case, we will explore targeting multiple pathways (3 or more) simultaneously, as our 
p5RHH peptide allows multiplexing option for multiple siRNAs.
Methods
p5RHH-siRNA NP Preparation. p5RHH peptide (VLTTGLPALISWIRRRHRRHC) provided by Genscript 
was dissolved at 20 mM in DNase-, RNase-, and protease- free sterile purified water (Cellgro) and stored in 10 μL 
aliquots at −80 °C before use. Human RELA SMART pool SiRNAs (a mixture of 4 different siRNAs at a ratio 
of 1:1:1:1; Cat# M-003533-02, Dharmacon) and ON-TARGETplus control Non-targeting pool siRNAs (Cat# 
D-001810-05, Dharmacon) were dissolved at 20 uM in DNase, RNase-, and protease- free sterile purified water 
(Cellgro) and stored in 10 μL aliquots at −80 °C until use.
For cell culture p5RHH siRNA NP was prepared by diluting p5RHH peptide (20 mM) 1:400 in Opti-MEM 
(Thermo Fisher Scientific), vortexed for 30 s followed by the addition of appropriate volume of RELA SMART 
pool or ON-TARGETplus control Non-targeting pool stock to achieve a peptide to siRNA ratio of 100 to 1. The 
mixture was incubated at 37 °C for 40 min with shaking.
For cartilage explant culture, the p5RHH siRNA NP was freshly prepared by mixing p5RHH peptide stock 
(20 mM) and siRNA (20 uM) to achieve a peptide to siRNA ratio of 1 to 10 in HBSS with Ca2+ and Mg2+ (Gibco, 
Life Technologies). The mixture was incubated on ice for 10 min and added directly to cartilage explants.
HUVEC culture. HUVECs procured from Sigma-Aldrich were seeded at low density in 12-well plates and 
cultured in Endothelial Cell Growth Medium (Cat# 50306188, Thermo Fisher Scientific) to 50% confluence. 
On the day of experiment, HUVECs were washed with warm Opti-MEM and siRNA-p5RHH NP was added to 
cells and incubated for 6 h in 1 ml Opti-MEM per well. Unbound complexes were removed and HUVECs were 
cultured for 72 h under regular conditions. Lipofectamine (RNAiMAX, Cat# 13778-030, Invitrogen) was used 
according manufacturer instructions. Cells were lysed directly in SDS sample buffer transferred to tubes, boiled 
for 10 min and stored at −20 °C until use.
Western blot analysis. Cell lysates were fractionated by SDS-PAGE under reducing condition and blot-
ted with rabbit anti-human p65 (1:1000, Cat# 33034, Cell Signaling) for 2 h at RT followed by incubation with 
HRP-conjugated Donkey anti-rabbit (Cat# 711-035-152, Jackson ImmunoResearch Laboratories). The bands 
were visualized using a SuperSignal West Pico Kit (Cat# 34080, Thermo Scientific,). The membrane was stripped 
and re-probed with anti-actin antibody (1:500, Cat# A2103, Sigma-Aldrich) to control for protein loading.
Human chondrocyte culture. All research involving human tissue was performed in accordance with 
relevant guidelines and regulations established by the Washington University in St. Louis Institutional Review 
Board (IRB) Committee. Human primary chondrocytes were isolated from the human cartilage obtained from 
discarded articular tissues harvested at the time of total knee arthroplasty from consented patients through a 
protocol approved by the IRB and all study participants provided written informed consent. The cartilage explants 
were maintained in 75 cm2 culture flasks in DMEM/F12 with 10% FBS, 100 U/ml penicillin, and 100 μg/ml 
streptomycin supplemented with 250 mg/L collagenase P and 250 mg/L Pronase for 15 h at 37 °C. The isolated 
cells were grown in 5% CO2 and 90% humidity at 37 °C. Cell viability was evaluated routinely by trypan blue 
exclusion method using a hemocytometer. Primary human chondrocytes were seeded on chamber slides and 
transfected with p5RHH-Cy3–labeled siRNA NP for 48 h, after which the chambers were washed with PBS, the 
cells were fixed and stained with F-actin (1:1000, Cat# ab176753, Abcam). Chamber slides were mounted with 
VECTASHIELD mounting medium with DAPI (Cat# H-1200, Vector Laboratories) and images were acquired 
using confocal microscopy.
Human cartilage explant culture. Human cartilage explants were obtained as described above. The 
de-identified cartilage tissues were washed several times with HBSS containing antibiotics then incubated in 
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DMEM/F12 (1:1) medium containing 10% FBS, penicillin/streptomycin (100 U/0.1 mg/mL), amphotericin 
B (0.25 μg/mL), and ciproflaxin (10 μg/mL) in a 6-well plate at 37 °C and 5% CO2 for 2–3 days. The explants 
were then transferred to a 96-well plate and were treated with IL-1β (10 ng/ml, Cat# PHC0815, Thermo Fisher 
Scientific Inc.) and subsequently exposed to p5RHH-p65 siRNA or scrambled siRNA (at a final concentration 
of 500 nM of siRNA) for 48 h. The excess NP was washed off after 48 h incubation and the explants were cultured 
in medium supplemented with IL-1β (10 ng/ml) for up to 28 days. The cartilage explants were then embedded 
in Tissue-Tek Optimal Cutting Temperature (O.C.T.) compound (Sakura Finetek USA, Inc.) and sectioned for 
analysis.
Immunofluorescence and confocal microscopy. Frozen sections (9 μm thick) were fixed and perme-
abilized with 0.5% Tween-20/PBS if needed and blocked with 8% BSA or Tyramide Signal Amp (TSA) blocking 
solution for 1 h at room temperature. After blocking the sections were incubated with the primary antibodies: 
anti-LC3 (1:100, Cat# L7543, Sigma-Aldrich), phospho-p65 (1:100, ab28856, Abcam), β-catenin (1:100, Cat# 
ab16051, Abcam), cleaved PARP (1:100, Cat# 9544, Cell Signaling), WNT16 (1:100, Cat# LS-A9629, LifeSpan 
Biosciences), WNT3A (1:100, Cat# OABF00803, Aviva Systems Biology), C3 (1:200, Cat# 55463, MP Biomedicals) 
overnight at 4 °C. After washing the sections were incubated with the corresponding HRP-conjugated secondary 
antibodies. All the sections were applied with Biotinyl Tyramide working solution (1:100) for 7 min to enhance 
the specific signal and subsequently incubated with Alexa Fluor 488-conjugated–streptavidin (1:200, Cat# 
S-11223, Molecular Probes) for 1 h. The sections were probed with COL2 antibody (1:200, generously provided 
by L. J. Sandell and M. F. Rai, Washington University, St. Louis) followed by TRITC-conjugated anti-rat secondary 
antibody (1:100, Cat# 712-295-153, Jackson ImmunoResearch) and counterstained with DAPI (1:1,000, Vector 
Laboratories). The images were acquired with ZEISS LSM 880 Confocal Laser Scanning Microscope and 15 to 20 
cells per section and 3–4 sections were analyzed with software ZEN. The data was presented as the mean fluores-
cent intensity per cell or ratio of positive cells.
Statistics. Comparisons between multiple groups (≥3) were performed by one-way ANOVA followed by 
Bonferroni’s correction for multiple comparisons was performed. Differences between experimental groups at a 
P value of <0.05 and a statistical power of 0.80 were considered significant.
Data Availability
Data generated in this current study are available from the corresponding author on reasonable request. The ma-
terials used to formulate nanoparticles are obtained from commercial vendors and methods are detailed in this 
study and through public searchable databases.
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